Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals, Inc.

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies.

Actinium Pharmaceuticals, Inc. | 13,072 followers on LinkedIn. Targeted Therapies for Patients with Unmet Needs | Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT

Vice President, Patent and Legal Counsel at Actinium Pharmaceuticals, Inc.

Paul Diamond

Biotech Executive | Finance & Operations | Biotech Growth Specialist | Vice President, Finance @ Actinium Pharmaceuticals

Steve Dressel

Gary Siegel

Chief Business Officer

Lynn Bodarky

Actinium Pharmaceuticals (NYSE: ATNM) Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors. Read the press release here: https://bit.ly/4eftEdy

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology. Read the press release here: https://bit.ly/3MOAuf4 #AML #Radiotherapies

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. Read the press release here: https://bit.ly/3Ad5jXP

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted #Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications. Read the press release here: https://bit.ly/3A2I02C #CARTcelltherapy #CellTherapy

Actinium (NYSE: ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for #SickleCellDisease Patients Undergoing #BoneMarrowTransplant in Collaboration with Columbia University. Read the press release here: https://bit.ly/3A8BnvC #BMT

Actinium Pharmaceuticals (NYSE: ATNM) to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US. Read the press release here: https://bit.ly/3YfmQZ9 #Radiotherapy

#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX

#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3

Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ

Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies

Metric
Company Name	Actinium Pharmaceuticals, Inc.
Symbol	ATNM
MSH ID	COM:ACTINIUMPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	49
Website	actiniumpharma.com
LinkedIn
Founders

Metric
Market Cap	210.57M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	81K
Revenue (LTM)
Revenue (NTM)
Gross Profit	81K
EBITDA	-51.92M
Operating Income	-51.92M
Net Income	-48.82M
EPS	-183.50
Diluted EPS	-183.50
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-5.60
Operating Profit Margin	-463.75
EBITDA Margin	-640.99
Net Profit Margin	-429.39
Return on Equity	-0.89
Return on Assets	-0.53
Return on Capital Employed	-0.62

COM:ACTINIUMPHARMA

Actinium Pharmaceuticals, Inc.

Last Close

1.39

21/11 21:00

Market Cap

210.57M

Beta: -

Volume Today

5.10K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.88
P/B Ratio	3.23
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.29K
EV Multiple	-6.39

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-3.33K
Asset Turnover	0.00

Metric
Operating Cash Flow	-47.34M
Free Cash Flow	-47.49M
Cash Flow to Debt	-20.00
Operating Cash Flow/Sales	-417.75
Free Cash Flow Yield	-0.33

Metric
Cash & Equivalents	76.68M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.05
Debt to Assets	0.02
Current Ratio	9.87
Quick Ratio	10.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	34.16
R&D to Revenue	332.32
SG&A to Revenue	131.43